Technology area: Biotechnology & Pharmaceuticals
6 pending office actions • 6 art units • 6 examiners • 0 of 6 (0%) have an AI response strategy ready • 1 patents granted in the last 365 days
CZ Biohub SF LLC has 6 pending office actions in Biotechnology & Pharmaceuticals. The matters involve 6 distinct examiners and 6 distinct art units. Each action therefore has its own examiner and art-unit assignment, producing a fully distributed examination profile within the reported docket.
ELENISTE, PIERRE PAUL is the busiest examiner, with 1 pending matter. No examiner carries more than that reported amount, so the docket does not support a dominant examiner strategy. Counsel should maintain separate matter histories and coordinate at the portfolio level for claim scope and response timing.
The absence of shared examiner or art-unit assignments makes file-level review particularly important. Counsel may still identify common technical or claim themes, but the available data does not establish those relationships. Any coordinated amendment or argument should therefore be based on the actual prosecution records.
Based on the USPTO statutory response window for each pending office action. 1 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §101 + other | 1 (17%) |
| §103 only | 2 (33%) |
| §112 only | 1 (17%) |
| Multi-statute (no §101) | 2 (33%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| ELENISTE, PIERRE PAUL | 1 | 35.4% | +31.1% |
| MOSSBROOK, WILLIAM ERIC | 1 | 53.7% | +75.5% |
| PARISI, JESSICA DANIELLE | 1 | 75.0% | +33.5% |
| KIM, YOUNG J | 1 | 64.8% | +18.2% |
| GOLDBERG, JEANINE ANNE | 1 | 45.4% | +40.5% |
| OGUNTADE, ELIZABETH BISOLA | 1 | 50.0% | +100.0% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 3 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 17923672 | MEASUREMENT OF AFUCOSYLATED IGG FC GLYCANS AND RELATED COVID-19 TREATMENT METHODS | OGUNTADE, ELIZABETH BISOLA | 70d |
| 18563310 | METHOD FOR PRODUCING A POPULATION OF SYMMETRICALLY BARCODED TRANSPOSOMES | PARISI, JESSICA DANIELLE | — |
| 18286685 | PROFILING CELL TYPES IN CIRCULATING NUCLEIC ACID LIQUID BIOPSY | GOLDBERG, JEANINE ANNE | — |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 6 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 17923672 | MEASUREMENT OF AFUCOSYLATED IGG FC GLYCANS AND RELATED COVID-19 TREATMENT METHODS | OGUNTADE, ELIZABETH BISOLA | 70d |
| 18838647 | COMPOSITIONS AND METHODS FOR INHIBITING FSP1 | ELENISTE, PIERRE PAUL | — |
| 18835705 | One Gram Penny-Sized Wireless EEG Recording Patch for Long-Term Mental Health Monitoring | MOSSBROOK, WILLIAM ERIC | — |
| 18563310 | METHOD FOR PRODUCING A POPULATION OF SYMMETRICALLY BARCODED TRANSPOSOMES | PARISI, JESSICA DANIELLE | — |
| 18563307 | METHODS FOR FRAGMENTING COMPLEMENTARY DNA | KIM, YOUNG J | — |
| 18286685 | PROFILING CELL TYPES IN CIRCULATING NUCLEIC ACID LIQUID BIOPSY | GOLDBERG, JEANINE ANNE | — |
| Art Unit | Apps |
|---|---|
| 1622 | 1 |
| 3794 | 1 |
| 1684 | 1 |
| 1681 | 1 |
| 1682 | 1 |
| 1677 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18838647 | COMPOSITIONS AND METHODS FOR INHIBITING FSP1 | ELENISTE, PIERRE PAUL | 1622 | §112 | Non-Final OA | — | Pending | Aug 15, 2024 |
| 18835705 | One Gram Penny-Sized Wireless EEG Recording Patch for Long-Term Mental Health Monitoring | MOSSBROOK, WILLIAM ERIC | 3794 | §103 | Final Rejection | — | Pending | Aug 02, 2024 |
| 18563310 | METHOD FOR PRODUCING A POPULATION OF SYMMETRICALLY BARCODED TRANSPOSOMES | PARISI, JESSICA DANIELLE | 1684 | §102§103§112 | Non-Final OA | — | Pending | Nov 21, 2023 |
| 18563307 | METHODS FOR FRAGMENTING COMPLEMENTARY DNA | KIM, YOUNG J | 1681 | §103 | Final Rejection | — | Pending | Nov 21, 2023 |
| 18286685 | PROFILING CELL TYPES IN CIRCULATING NUCLEIC ACID LIQUID BIOPSY | GOLDBERG, JEANINE ANNE | 1682 | §101§102§103§112 | Non-Final OA | — | Pending | Oct 12, 2023 |
| 17923672 | MEASUREMENT OF AFUCOSYLATED IGG FC GLYCANS AND RELATED COVID-19 TREATMENT METHODS | OGUNTADE, ELIZABETH BISOLA | 1677 | §103§112Other | Final Rejection | 70d | Pending | Nov 07, 2022 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free TrialCZ Biohub SF LLC has 6 pending office actions as of October 2026, spread across 6 art units and 6 examiners.
Pierre Paul Eleniste has the most, with 1 of CZ Biohub SF LLC's pending office actions.
Mostly Biotechnology & Pharmaceuticals (USPTO Tech Center 1600), based on where its pending office actions are examined.
